Article PDF
References
Mauger TF, Elson CL editors. Ocular pharmacology. 6th ed. St Louis: Mosby, 1994:89, 144–5, 177-8.
Cantor LB, Burke J . Drug evaluation: brimonidine. Expert Opin Invest Drugs 1997;6:1063–83.
Toris CB, Gleason ML, Camras CB, et al. Effects of brimonidine on aqueous humour dynamics in human eyes. Arch Ophthalmol 1995;113:1514–7.
Walters TR . Development and use of brimonidine in treating acute and chronic elevations of intraocular pressure: a review of safety, efficacy, dose response, and dosing studies. Surv Ophthalmol 1996;41(Suppl 1):19–26.
Karcioglu ZA, Mullaney PB . Diagnosis and management of iris juvenile xanthogranuloma. J Pediatr Ophthalmol Strabismus 1997;34:44–51.
Casteels I, Olver J, Malone M, et al. Early treatment of juvenile xanthogranuloma of the iris with subconjunctival steroids. Br J Ophthalmol 1993;77:57–60.
Hadden OB . Bilateral juvenile xanthogranuloma of the iris. Br J Ophthalmol 1975;59:699–702.
MacLeod PM . Case report: juvenile xanthogranuloma of the iris managed with superficial radiotherapy. Clin Radiol 1986;37:295–6.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Walters, G., Taylor, R. Severe systemic toxicity caused by brimonidine drops in an infant with presumed juvenile xanthogranuloma. Eye 13, 797–798 (1999). https://doi.org/10.1038/eye.1999.235
Issue Date:
DOI: https://doi.org/10.1038/eye.1999.235
This article is cited by
-
Pediatric Glaucoma: Pharmacotherapeutic Options
Pediatric Drugs (2016)
-
Ocular and systemic side effects of brimonidine 0.2% eye drops (Alphagan®) in children
Eye (2004)